Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory

Abstract

IntroductionDiabetes is a highly prevalent disease worldwide and represents a challenge for patients and healthcare systems. This population-based study evaluated diabetes burden in Italy in 2018 by assessing all aspects of outpatient and hospital care.Research design and methodsWe investigated data of 11 300 750 residents in local health districts contributing to ARNO Diabetes Observatory (~20% of Italian inhabitants). All administrative healthcare claims were analyzed to gather information on access to medical resources. Subjects with diabetes, identified by antihyperglycemic drug prescriptions, disease-specific copayment exemption and hospital discharge codes, were compared with age, sex and residency-matched non-diabetic individuals.ResultsWe identified 697 208 subjects with ascertained diabetes, yielding a prevalence of 6.2% (6.5% in men vs 5.9% in women, p<0.001). Age was 69±15 (mean±SD). As compared with non-diabetic subjects, patients with diabetes received more prescriptions of any drugs (+30%, p<0.001), laboratory tests, radiologic exams and outpatient specialist consultations (+20%, p<0.001) and were hospitalized more frequently (+86%, p<0.001), with a longer stay (+1.4 days, p<0.001). Although cardiovascular diseases accounted for many hospital discharge diagnoses, virtually all diseases contributed to the higher rate of hospital admissions in diabetic subjects (235 vs 99 per 1000 person-years, p<0.001). Healthcare costs were >2-fold higher in subjects with diabetes, mainly driven by hospitalizations and outpatient care related to chronic complications rather than to glucose-lowering drugs, diabetes-specific devices, or metabolic monitoring.ConclusionsThe burden of diabetes in Italy is particularly heavy and, as a systemic disease, it includes all aspects of clinical medicine, with consequent high expenses in all areas of healthcare.

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

“…DPP4 inhibitors (DPP4i) are widely used for the treatment of type 2 diabetes [ 15 ]. For example in Italy, it has become one of the most popular second-line glucose-lowering medications (GLMs) [ 16 , 17 ], thanks to their optimal safety and tolerability profile. Since quite limited treatment options are available against COVID-19 and there is basically no pharmaceutical strategy to prevent SARS‐CoV‐2 infection, DPP4i have been hypothesized to represent a potential approach [ 18 ].…”

Bidirectional Association between Metabolic Control in Type-2 Diabetes Mellitus and Periodontitis Inflammatory Burden: A Cross-Sectional Study in an Italian Population

“…The aims of the present cross-sectional study were to determine the periodontal health status of T2DM patients attending an Outpatient Diabetes Center in North Italy [ 26 ] and to assess the association between glycemic control and periodontitis, as measured clinically and with the PISA Index.…”

Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes

“…We also would like to note that the target population addressed in this study might not be representative of patients with T2D in other countries. We included only patients followed at specialist outpatient clinics because, in Italy, only diabetes specialists but not general practitioners, can prescribe GLP-1RA, SGLT2i and DPP-4i [ 20 ]. Therefore, further transferability of our findings to the general population of patients with T2D, including those not attending diabetes clinics, needs confirmation.…”

“…All patients aged 18 years or older and with a diagnosis of T2D were included, yielding a population of about 281,000 patients, evaluated between 2015 and 2016. Therefore, this was an unselected population of adults with T2D attending diabetes clinics, which is estimated to represent about 20% of the entire population of individuals with T2D attending diabetes clinics in Italy [ 20 , 21 ]. Study design and methods for data collection, including definition of variables, have been described previously in detail [ 17 ].…”